← Back to Search

Stem Cell Therapy

hMSC for Coronavirus

Q: Are there any vacancies available for participants of this experiment?

Assessed by clinicaltrials.gov, this medical study is currently open to patient recruitment. It was first posted on March 20th 2021 and most recently amended on July 7th 2022.

Q: What is the current participation rate of this research endeavor?

Affirmative. According to the clinicaltrials.gov portal, this investigation is actively recruiting participants; it was posted on March 20th 2021 and has recently been updated on July 7th 2022. The study seeks 40 volunteers from 2 different medical centres.

Q: Has the FDA verified hMSC as a viable therapeutic option?

Based on the evidence gathered, we have given hMSC a safety score of 2 since there is only limited proof that this treatment has any efficacy. However, there are several studies which demonstrate its relative security.

Phase 2

Recruiting

Led By Santosh Kesari, MD

Research Sponsored by Stemedica Cell Technologies, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Laboratory-confirmed diagnosis of COVID-19 <= 14 days prior to randomization

Bilateral chest radiograph infiltrates.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 9 months

Awards & highlights

Study Summary

This trial is testing if an experimental antibody drug can improve lung function in patients with moderate to severe lung injury from COVID-19 or other potential viral and bacterial pathogens.

Eligible Conditions

Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Survival

Secondary outcome measures

Number of patients with treatment-related adverse events as assessed by CTCAE v4.0

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: hMSCsExperimental Treatment1 Intervention

hMSCs will be given via IV administration.

Group II: Lactated Ringer's SolutionPlacebo Group1 Intervention

Lactated Ringer's Solution will be given via IV administration.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stemedica Cell Technologies, Inc.Lead Sponsor

5 Previous Clinical Trials

130 Total Patients Enrolled

bioRASI, LLCIndustry Sponsor

13 Previous Clinical Trials

3,616 Total Patients Enrolled

Lev Verkh, PhD/MSStudy DirectorStemedica Cell Technologies, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies available for participants of this experiment?

"Assessed by clinicaltrials.gov, this medical study is currently open to patient recruitment. It was first posted on March 20th 2021 and most recently amended on July 7th 2022."

Answered by AI

What is the current participation rate of this research endeavor?

"Affirmative. According to the clinicaltrials.gov portal, this investigation is actively recruiting participants; it was posted on March 20th 2021 and has recently been updated on July 7th 2022. The study seeks 40 volunteers from 2 different medical centres."

Answered by AI

Has the FDA verified hMSC as a viable therapeutic option?

"Based on the evidence gathered, we have given hMSC a safety score of 2 since there is only limited proof that this treatment has any efficacy. However, there are several studies which demonstrate its relative security."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

2021. "A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04780685.